Nautilus Biotechnology focuses on developing technologies for protein analysis and discovery.
Nautilus's iterative mapping technology creates 3D protein models by observing binding kinetics, overcoming mass spectroscopy's epistemic ceiling (cannot distinguish proteoforms with identical mass). This foundational platform enables predictive peptide therapies across Alzheimer's (tau assay launched), Parkinson's (alpha-synuclein in progress), oncology, immunology, and cardiology, positioning it for a potential $100T longevity-as-a-service market.